Ghost Tree Capital’s Medicines Co MDCO Stock Holding History

Ghost Tree Capital’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-75,000	Closed	-$2.55M	–	91
2016 Q4	$2.55M	Buy	+75,000	New	+$2.66M	0.61%	51

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Ghost Tree Capital's MDCO Position: Q1 2017 in Review

Ghost Tree Capital sold out of Medicines Co (MDCO) in Q1 2017, closing a stake of 75,000 shares — an estimated $2.55M sold.

Ghost Tree Capital first reported a position in MDCO in Q4 2016 and held it in 1 quarter. The position peaked at $2.55M in Q4 2016. 220 funds tracked by Wall St. Rank hold MDCO as of Q1 2017.

Ghost Tree Capital reported no remaining Medicines Co position as of Q1 2017 after selling out during the quarter.
Ghost Tree Capital sold 75,000 Medicines Co shares in Q1 2017, an estimated $2.55M.
Ghost Tree Capital first reported a position in Medicines Co in Q4 2016 and held it in 1 quarter.
Ghost Tree Capital's Medicines Co position peaked at $2.55M in Q4 2016.
220 funds tracked by Wall St. Rank held Medicines Co as of Q1 2017.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.